Racura Oncology

Why Invest

Updates

Announcements

Home

Inter

Racura Oncology InvestorHub

Race Oncology joins four other biotech companies to present at HealthInvest 2024, hosted by IR Department and Morgans Financial Group.

At the conference, Race presented the clinical development history of its lead asset bisantrene, and the pipeline for the coming months to investors, analysts and industry peers in the room. 

Watch the interview with Dr Peter Smith, Race's Executive Chair below. Full article on the conference can be accessed here. 

Race presents at HealthInvest 2024